Shuxing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shuxing Zhang has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
- Zhi Tan
Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA
20 shared publications - Varsha Gandhi
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
13 shared publications - Abdelraouf Eldeib
Department of Internal Medicine, College of Medicine, Suez Canal University, Ismailia, Egypt
12 shared publications - Aloke Sarkar
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
12 shared publications - Shady Ibrahim Tantawy
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
12 shared publications - Stefan Hubner
Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston, TX 78712, USA
12 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Table S1- CLL Patient CharacteristicsSupplemental Table S2. Name and source of antibodiesSupplemental Table 3 - RT-PCR Primers
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Table S1- CLL Patient CharacteristicsSupplemental Table S2. Name and source of antibodiesSupplemental Table 3 - RT-PCR Primers
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Figure S1. Changes in protein expression levels induced by MCL-1 inhibitor. Supplemental Figure S2. Impact of MCL-1 inhibitors on total Mcl-1, T163 and S159 phosphorylation.Supplemental Figure S3. MCL-1 inhibitors induce a transient decrease in Mule.Supplemental Figure S4. In vitro De-ubiquitinating activity assay of USP9x with MCL-1 inhibitors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Figure S1. Changes in protein expression levels induced by MCL-1 inhibitor. Supplemental Figure S2. Impact of MCL-1 inhibitors on total Mcl-1, T163 and S159 phosphorylation.Supplemental Figure S3. MCL-1 inhibitors induce a transient decrease in Mule.Supplemental Figure S4. In vitro De-ubiquitinating activity assay of USP9x with MCL-1 inhibitors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Figure S1. Changes in protein expression levels induced by MCL-1 inhibitor. Supplemental Figure S2. Impact of MCL-1 inhibitors on total Mcl-1, T163 and S159 phosphorylation.Supplemental Figure S3. MCL-1 inhibitors induce a transient decrease in Mule.Supplemental Figure S4. In vitro De-ubiquitinating activity assay of USP9x with MCL-1 inhibitors.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Figure S1. Changes in protein expression levels induced by MCL-1 inhibitor. Supplemental Figure S2. Impact of MCL-1 inhibitors on total Mcl-1, T163 and S159 phosphorylation.Supplemental Figure S3. MCL-1 inhibitors induce a transient decrease in Mule.Supplemental Figure S4. In vitro De-ubiquitinating activity assay of USP9x with MCL-1 inhibitors.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Table S1- CLL Patient CharacteristicsSupplemental Table S2. Name and source of antibodiesSupplemental Table 3 - RT-PCR Primers
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Table S1- CLL Patient CharacteristicsSupplemental Table S2. Name and source of antibodiesSupplemental Table 3 - RT-PCR Primers
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Purpose:Several MCL-1 inhibitors (MCL-1i), including AMG-176 and AZD5991, have shown promise in preclinical studies and are being tested for the treatment of hematologic malignancies. A unique feature of these agents is induction and stability of Mcl-1 protein; however, the precise mechanism is unknown. We aim to study the mechanism of MCL-1i–induced Mcl-1 protein stability.Experimental Design:Using several B-cell leukemia and lymphoma cell lines and primary chronic lymphocytic leukemia (CLL) lymphocytes, we evaluated molecular events associated with Mcl-1 protein stability including protein half-life, reverse-phase protein array, protein–protein interaction, phosphorylation, ubiquitination, and de-ubiquitination, followed by molecular simulation and modeling.Results:Using both in vivo and in vitro analysis, we demonstrate that MCL-1i–induced Mcl-1 protein stability is predominantly associated with defective Mcl-1 ubiquitination and concurrent apoptosis induction in both cell lines and primary CLL subjects. These MCL1i also induced ERK-mediated Mcl-1Thr163 phosphorylation, which partially contributed to Mcl-1 stability. Disruption of Mcl-1:Noxa interaction followed by Noxa degradation, enhanced Mcl-1 de-ubiquitination by USP9x, and Mule destabilization are the major effects of these inhibitors. However, unlike other BH3 proteins, Mule:Mcl-1 interaction was unaffected by MCL-1i. WP1130, a global deubiquitinase (DUB) inhibitor, abrogated Mcl-1 induction reaffirming a critical role of DUBs in the observed Mcl-1 protein stability. Further, in vitro ubiquitination studies of Mcl-1 showed distinct difference among these inhibitors.Conclusions:We conclude that MCL-1i blocked Mcl-1 ubiquitination via enhanced de-ubiquitination and dissociation of Mcl-1 from Noxa, Bak and Bax, and Mule de-stabilization. These are critical events associated with increased Mcl-1 protein stability with AMG-176 and AZD5991.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Purpose:Several MCL-1 inhibitors (MCL-1i), including AMG-176 and AZD5991, have shown promise in preclinical studies and are being tested for the treatment of hematologic malignancies. A unique feature of these agents is induction and stability of Mcl-1 protein; however, the precise mechanism is unknown. We aim to study the mechanism of MCL-1i–induced Mcl-1 protein stability.Experimental Design:Using several B-cell leukemia and lymphoma cell lines and primary chronic lymphocytic leukemia (CLL) lymphocytes, we evaluated molecular events associated with Mcl-1 protein stability including protein half-life, reverse-phase protein array, protein–protein interaction, phosphorylation, ubiquitination, and de-ubiquitination, followed by molecular simulation and modeling.Results:Using both in vivo and in vitro analysis, we demonstrate that MCL-1i–induced Mcl-1 protein stability is predominantly associated with defective Mcl-1 ubiquitination and concurrent apoptosis induction in both cell lines and primary CLL subjects. These MCL1i also induced ERK-mediated Mcl-1Thr163 phosphorylation, which partially contributed to Mcl-1 stability. Disruption of Mcl-1:Noxa interaction followed by Noxa degradation, enhanced Mcl-1 de-ubiquitination by USP9x, and Mule destabilization are the major effects of these inhibitors. However, unlike other BH3 proteins, Mule:Mcl-1 interaction was unaffected by MCL-1i. WP1130, a global deubiquitinase (DUB) inhibitor, abrogated Mcl-1 induction reaffirming a critical role of DUBs in the observed Mcl-1 protein stability. Further, in vitro ubiquitination studies of Mcl-1 showed distinct difference among these inhibitors.Conclusions:We conclude that MCL-1i blocked Mcl-1 ubiquitination via enhanced de-ubiquitination and dissociation of Mcl-1 from Noxa, Bak and Bax, and Mule de-stabilization. These are critical events associated with increased Mcl-1 protein stability with AMG-176 and AZD5991.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Purpose:Several MCL-1 inhibitors (MCL-1i), including AMG-176 and AZD5991, have shown promise in preclinical studies and are being tested for the treatment of hematologic malignancies. A unique feature of these agents is induction and stability of Mcl-1 protein; however, the precise mechanism is unknown. We aim to study the mechanism of MCL-1i–induced Mcl-1 protein stability.Experimental Design:Using several B-cell leukemia and lymphoma cell lines and primary chronic lymphocytic leukemia (CLL) lymphocytes, we evaluated molecular events associated with Mcl-1 protein stability including protein half-life, reverse-phase protein array, protein–protein interaction, phosphorylation, ubiquitination, and de-ubiquitination, followed by molecular simulation and modeling.Results:Using both in vivo and in vitro analysis, we demonstrate that MCL-1i–induced Mcl-1 protein stability is predominantly associated with defective Mcl-1 ubiquitination and concurrent apoptosis induction in both cell lines and primary CLL subjects. These MCL1i also induced ERK-mediated Mcl-1Thr163 phosphorylation, which partially contributed to Mcl-1 stability. Disruption of Mcl-1:Noxa interaction followed by Noxa degradation, enhanced Mcl-1 de-ubiquitination by USP9x, and Mule destabilization are the major effects of these inhibitors. However, unlike other BH3 proteins, Mule:Mcl-1 interaction was unaffected by MCL-1i. WP1130, a global deubiquitinase (DUB) inhibitor, abrogated Mcl-1 induction reaffirming a critical role of DUBs in the observed Mcl-1 protein stability. Further, in vitro ubiquitination studies of Mcl-1 showed distinct difference among these inhibitors.Conclusions:We conclude that MCL-1i blocked Mcl-1 ubiquitination via enhanced de-ubiquitination and dissociation of Mcl-1 from Noxa, Bak and Bax, and Mule de-stabilization. These are critical events associated with increased Mcl-1 protein stability with AMG-176 and AZD5991.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Purpose:Several MCL-1 inhibitors (MCL-1i), including AMG-176 and AZD5991, have shown promise in preclinical studies and are being tested for the treatment of hematologic malignancies. A unique feature of these agents is induction and stability of Mcl-1 protein; however, the precise mechanism is unknown. We aim to study the mechanism of MCL-1i–induced Mcl-1 protein stability.Experimental Design:Using several B-cell leukemia and lymphoma cell lines and primary chronic lymphocytic leukemia (CLL) lymphocytes, we evaluated molecular events associated with Mcl-1 protein stability including protein half-life, reverse-phase protein array, protein–protein interaction, phosphorylation, ubiquitination, and de-ubiquitination, followed by molecular simulation and modeling.Results:Using both in vivo and in vitro analysis, we demonstrate that MCL-1i–induced Mcl-1 protein stability is predominantly associated with defective Mcl-1 ubiquitination and concurrent apoptosis induction in both cell lines and primary CLL subjects. These MCL1i also induced ERK-mediated Mcl-1Thr163 phosphorylation, which partially contributed to Mcl-1 stability. Disruption of Mcl-1:Noxa interaction followed by Noxa degradation, enhanced Mcl-1 de-ubiquitination by USP9x, and Mule destabilization are the major effects of these inhibitors. However, unlike other BH3 proteins, Mule:Mcl-1 interaction was unaffected by MCL-1i. WP1130, a global deubiquitinase (DUB) inhibitor, abrogated Mcl-1 induction reaffirming a critical role of DUBs in the observed Mcl-1 protein stability. Further, in vitro ubiquitination studies of Mcl-1 showed distinct difference among these inhibitors.Conclusions:We conclude that MCL-1i blocked Mcl-1 ubiquitination via enhanced de-ubiquitination and dissociation of Mcl-1 from Noxa, Bak and Bax, and Mule de-stabilization. These are critical events associated with increased Mcl-1 protein stability with AMG-176 and AZD5991.
- Open Access
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Figure S1. Changes in protein expression levels induced by MCL-1 inhibitor. Supplemental Figure S2. Impact of MCL-1 inhibitors on total Mcl-1, T163 and S159 phosphorylation.Supplemental Figure S3. MCL-1 inhibitors induce a transient decrease in Mule.Supplemental Figure S4. In vitro De-ubiquitinating activity assay of USP9x with MCL-1 inhibitors.
- 1 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Supplemental Figure S1. Changes in protein expression levels induced by MCL-1 inhibitor. Supplemental Figure S2. Impact of MCL-1 inhibitors on total Mcl-1, T163 and S159 phosphorylation.Supplemental Figure S3. MCL-1 inhibitors induce a transient decrease in Mule.Supplemental Figure S4. In vitro De-ubiquitinating activity assay of USP9x with MCL-1 inhibitors.